Skip to main content

Protara Therapeutics, Inc.

corporate_fare Company Profile

Protara Therapeutics, Inc.

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy for patients receiving parenteral nutrition and fluids. The company is headquartered in New York, New York.

Exchange: NASDAQSector: Life Sciences

show_chartPrice Chart

Loading chart...

feed TARA - Latest Insights

TARA
Apr 23, 2026, 8:42 PM EDT
Filing Type: 144
Importance Score:
7
TARA
Apr 23, 2026, 8:41 PM EDT
Filing Type: 144
Importance Score:
7
TARA
Apr 17, 2026, 4:15 PM EDT
Filing Type: PRE 14A
Importance Score:
9
TARA
Mar 10, 2026, 8:11 AM EDT
Filing Type: 10-K
Importance Score:
8
TARA
Mar 10, 2026, 8:06 AM EDT
Filing Type: 8-K
Importance Score:
8
TARA
Mar 10, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
TARA
Mar 06, 2026, 5:51 PM EST
Filing Type: 144
Importance Score:
7
TARA
Mar 06, 2026, 5:50 PM EST
Filing Type: 144
Importance Score:
7
TARA
Mar 06, 2026, 4:15 PM EST
Filing Type: 424B7
Importance Score:
7
TARA
Mar 04, 2026, 8:37 PM EST
Filing Type: 144
Importance Score:
7
TARA
Mar 04, 2026, 8:35 PM EST
Filing Type: 144
Importance Score:
7
TARA
Feb 25, 2026, 7:58 PM EST
Filing Type: 144
Importance Score:
8
TARA
Feb 25, 2026, 7:57 PM EST
Filing Type: 144
Importance Score:
7
TARA
Feb 24, 2026, 9:13 PM EST
Filing Type: 144
Importance Score:
7
TARA
Feb 24, 2026, 8:52 AM EST
Filing Type: 8-K
Importance Score:
8